Navigation Links
Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing targeted monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced initiation of a new clinical trial designed to evaluate the safety and efficacy of its tumor necrosis therapy (TNT) agent Cotara(R) in patients with glioblastoma multiforme (GBM), a deadly form of brain cancer.

In pilot studies Cotara has shown encouraging results, demonstrating a 58% increase in the expected median survival time in a group of 28 patients suffering from recurrent late stage glioblastoma multiforme. This was considered a promising development in this serious and deadly disease, which kills half of its victims within 14 months of diagnosis.

Peregrine believes that combined positive data from this new study in India and ongoing U.S. glioblastoma trials would provide a foundation for advancing Cotara into Phase III trials.

"Cotara has demonstrated promising increases in survival in previous clinical studies of late stage glioblastoma patients, and we are optimistic that the very large population of glioblastoma patients served by our Indian study centers will facilitate timely enrollment in this important new trial," said Steven W. King, president and CEO of Peregrine. "We anticipate that positive data from this study, together with dosimetry and dosing data being collected in ongoing U.S. Cotara trials, will help us determine the optimal design of Phase III product registration trials."

This multi-center open label Phase II safety and efficacy study is designed to enroll up to 40 glioblastoma patients who have experienced a first relapse. The study's primary objective is to confirm the maximum tolerated dose of Cotara in patients with GBM at first relapse.

Secondary objectives include estimates of overall patient survival, progression free survival and the proportion of patien ts alive at six months. Patients in the trial are receiving a single infusion of Cotara by convection-enhanced delivery (CED), an NIH-developed technique that delivers the agent to the tumor with great precision, achieving up to a 10,000-fold greater concentration in local therapy exposure than conventional intravenous drug administration, while minimizing unwanted exposure to healthy tissue. This delivery method is expected to further enhance the tumor-killing efficacy of Cotara.

Mr. King continued, "We are launching this Cotara clinical program in India to take advantage of the large population of GBM patients served by our study centers and the high level of experience with CED delivery of the participating neurosurgeons, as well as the fact that the contract research organization overseeing the trial is highly experienced in conducting similar glioblastoma trials with many of the investigators involved with our study."

The new Cotara study is being conducted according to internationally accepted ICH GCP guidelines.


'"/>




Related medicine news :

1. FDA approves Watson Pharmaceuticals Oxytrol patch
2. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
3. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
4. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
5. Top Pharmaceuticals Influence Doctors Prescriptions
6. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
7. Personalized Medicine and Innovative Pharmaceuticals
8. Pravastatin Launched by Watson Pharmaceuticals
9. Tata Industries picks up stake in Indigene Pharmaceuticals
10. Pharmaceuticals May not Pose Major Aquatic Environmental Risks
11. OPPI Opposes Draft National Pharmaceuticals Policy
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/18/2017)... ... January 18, 2017 , ... From a health perspective, 2017 will clearly be ... health to chronic disease, mental health and general physical well-being. The New York Times ... to consider. , For one Charlottesville restaurant, good gut health is clearly on the ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... of Bioengineering are collaborating on a research project focused on multiple sclerosis (MS). ... seeks to use nanotechnology to control the disease without compromising normal immune function ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... leading journal and most-read publication among specialty pharmacists and pharmacy professionals, has ... its Strategic Alliance Partnership (SAP) program, announced Brian Haug, president of Pharmacy ...
(Date:1/18/2017)... Palm Beach, FL (PRWEB) , ... January 18, 2017 , ... ... as a fund raiser for Smile Train, an international charity that provides free surgery ... a hobby of mine and in the past I have run to support the ...
(Date:1/18/2017)... (PRWEB) , ... January 18, 2017 , ... The Portee ... to families and business owners in central Maryland and the DC region, is inaugurating ... disease kills 787,000 people nationally every year, making it the #1 killer in America. ...
Breaking Medicine News(10 mins):
(Date:1/18/2017)... India , January 18, 2017 ... Imaging Technologies Market by Type: Global Opportunity Analysis and Industry ... size was valued at $2,544 million in 2015 and is ... CAGR of 8.4% from 2016 to 2022. North ... accounted for over three-fourths market share in 2015. Ionizing breast ...
(Date:1/18/2017)... N.J. , Jan. 18, 2017   Regenicin, ... a biotechnology company specializing in the development and commercialization ... damaged tissues and organs, recently reported the Company,s operating ... for 2017. As the Company described in ... been a year of substantial accomplishments. The Company,s contract ...
(Date:1/18/2017)... , Suiza, 18 de enero de 2017 /PRNewswire/ ... líderes lanzaron Access Accelerated, una iniciativa global para avanzar ... (NCD) y atención en países de renta baja y ... han alcanzado un punto de crisis, particularmente en países ... el 80 por ciento de las muertes relacionadas con ...
Breaking Medicine Technology: